Celldex Therapeutics, Inc. (CLDX) vs SELLAS Life Sciences Group, Inc. (SLS)

Celldex Therapeutics, Inc. and SELLAS Life Sciences Group, Inc. are both Biotechnology companies. Celldex Therapeutics, Inc. and SELLAS Life Sciences Group, Inc. are of similar size ($2.5B and $2.4B). SELLAS Life Sciences Group, Inc. has the higher net margin (0.00% vs −33,883.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, SELLAS Life Sciences Group, Inc. leads on 12 and Celldex Therapeutics, Inc. on 3.

Valuation

Metric CLDX SLS Biotechnology median
P/E n/m n/m 7.88
P/S 2,729.23 209.18 11.47
P/B 3.39 15.96 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 1,923.07 196.06 10.73
Earnings yield (13.99%) (1.81%) (28.84%)
Free cash flow yield (10.00%) (1.75%) (23.03%)

Profitability

Metric CLDX SLS Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (36,733.82%) 0.00% 0.00%
Net margin (33,883.77%) 0.00% 0.00%
Free cash flow margin (27,294.81%) 0.00% 0.00%
Return on equity (43.88%) (39.63%) (57.72%)
Return on assets (40.76%) (36.54%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CLDX SLS Biotechnology median
Revenue growth (TTM) (88.27%) — 5.64%
EPS growth (last fiscal year) (59.18%) 50.00% —
Revenue growth, 5-year CAGR (26.93%) — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLDX SLS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.82 18.83 4.73
Net debt to EBITDA 1.78 2.54 0.96

Dividend

Metric CLDX SLS Biotechnology median
Dividend yield 2.16% — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CLDX SLS Biotechnology median
Market cap 2.49b 2.37b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack